React4Life, an Italian Biotech Company Raised Money with Equity Crowdfunding

New recognitions for React4life, a company that develops advanced technologies for biomedical research, already used by international giants such as Roche and Merck, based on the MIVO®- Multi-In-Vitro-Organ patent, an organ-on-chip system that allows the growth of cells or biological tissues in the laboratory, optimizing preclinical research.

In 2022, the company had concluded a round on CrowdFundMe with a collection of over €600,000 from 171 members, against a minimum target of 250,000 euros and a pre-money valuation of 16 million.

In 2023, React4Life value of production stood at €582,000, a sharp increase from €264,000 in 2022

Selected by the EU Commission among the 15 most innovative “Life Science” scaleups
React4life has been selected by the European Commission as one of the 15 most innovative scaleups in the life sciences sector in the EU. A milestone that allowed it to be present at the BIO 2024 fair in San Diego (USA), which was held between May and June, useful for showcasing itself on the US market.

As explained by the European Innovation Council on LinkedIn, the group of selected companies, “promoted by the EIC ITF 3.0 Programme, is looking forward to expanding globally”. And participation in BIO 2024 was an opportunity to “present their innovations within the European Pavilion, panels and networking events”, engaging with “potential customers, partners and investors”, and with the possibility to “build strategic ties” and “explore interesting business opportunities”.

In addition, the patent underlying React4life technology has also been approved in China and America this year. Finally, in recent months, React4life has started a new research program, co-financed by the Liguria Region, aimed at developing a new prototype of sensorized organ-on-chip.

Innovative technologies to accelerate medical research

React4life is an Italian biotech company founded in 2016, with the aim of developing innovative technologies for biomedical research – already used by large groups such as Roche and Merck – based on the MIVO®- Multi-In-Vitro-Organ patent. MIVO® is an organ-on-chip, i.e. a system that allows the growth of cells or biological tissues in the laboratory in conditions that recreate human biology, reducing the time and costs of preclinical research.

Medical research faces two major challenges: understanding the mechanisms underlying human diseases (such as cancer) and developing increasingly effective and safe drugs and vaccines.

It takes about 13 years and more than $1 billion for a new drug to reach the market; in fact, 80% of formulations fail human trials due to the low reliability of preclinical tests.

Researchers currently use traditional models that are not always comparable to the human body: cell culture in dishes or animal testing, which in Europe uses around 10 million animals per year.

MIVO® technology, thanks to its design and the integrability of its components, is able to replicate the processes and connections of the human body, being able to host different organs connected to each other, analyzing their interactions.

__

(Featured image by  WOKANDAPIX via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Crowdfunding buzz. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us